# Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

Source: https://onco.cc/trials/nct06297226/  
OnCo record `nct06297226` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Arlocabtagene Autoleucel in multiple myeloma, run by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, now recruiting.

## Summary

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma is a phase 2 interventional study registered as NCT06297226 by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, with 230 participants planned, started 2024-03-21 and due to reach its primary completion in 2026-07-31. Interventions recorded: Arlocabtagene Autoleucel. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06297226
- Phase: 2
- Setting: A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
- Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Enrolled: 230

## Sources

- ClinicalTrials.gov NCT06297226: https://clinicaltrials.gov/study/NCT06297226

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Arlocabtagene Autoleucel](https://onco.cc/drugs/arlocabtagene-autoleucel/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)

---
JSON: https://onco.cc/api/v1/entities/nct06297226.json